| 216.50 Real-Time Quote |  -3.14 / -1.43%Today’s Change | 134.21 Today|||52-Week Range 225.10 | +57.78% Year-to-Date |
The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc. The fund is non-diversified.
| 3 Biotech Flops of 2013 Dec 05 / MotleyFool.com | Morning Market Look-Biogen Explodes Nov 22 / StockTwits |
| Bear of the Day: SurModics (SRDX) - Bear of the Day Dec 04 / Zacks.com | Morning Market Look: Serepta Disappoints Nov 12 / StockTwits |
| Are Biotech ETFs Back on Track? - ETF News And Commentary Dec 04 / Zacks.com |
| 1 month | +8.43% | 3 years | +35.25% | |
| 3 months | +7.71% | 5 years | +27.81% | |
| 1 year | +61.80% | Since inception | +6.54% |
| Previous close | $219.64 |
| Open day’s range | 216.31 – 219.53 |
| Net asset value (NAV) | 221.46 (12/09/2013) |
| Daily volume | 216,043 |
| Average volume (3 months) | 964,948 |
| IBB | Category | |
|---|---|---|
| Performance 5-yr return | +27.81% | +15.83% |
| Expense Gross exp ratio | 0.48% | 0.43% |
| Risk 5 year sharpe ratio | 1.44 | 1.36 |
| Net assets | $4.4B | $1.1B |
| Average market cap | $12.5B | $24.0B |
| Average P/E | 30.1 | 25.7 |
| Dividend / Share | -- | 0.22% |
| VHT Vanguard Health Care ETF |
| RYH Guggenheim S&P 500 Equal Weight Healthca... |
| XLV Health Care Select Sector SPDR Fund |
| Healthcare | 99.91% |
| Business service | 0.09% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| BIIB Biogen Idec Inc | 9.65% |
| GILD Gilead Sciences Inc | 8.77% |
| CELG Celgene Corporation | 8.16% |
| AMGN Amgen Inc | 7.40% |
| REGN Regeneron Pharmaceuticals, Inc. | 6.98% |
| MYL Mylan Inc | 4.36% |
| ALXN Alexion Pharmaceuticals, Inc. | 4.08% |
| VRTX Vertex Pharmaceuticals | 3.26% |
| ILMN Illumina, Inc. | 3.17% |
| BMRN Biomarin Pharmaceutical, Inc. | 2.55% |
.
